172 related articles for article (PubMed ID: 15948220)
1. BRAF mutation detection and identification by cycling temperature capillary electrophoresis.
Hinselwood DC; Abrahamsen TW; Ekstrøm PO
Electrophoresis; 2005 Jun; 26(13):2553-61. PubMed ID: 15948220
[TBL] [Abstract][Full Text] [Related]
2. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
3. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
4. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
Schulten HJ; Al-Maghrabi J; Al-Ghamdi K; Salama S; Al-Muhayawi S; Chaudhary A; Hamour O; Abuzenadah A; Gari M; Al-Qahtani M
Anticancer Res; 2011 Dec; 31(12):4179-83. PubMed ID: 22199277
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
6. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
Ney JT; Froehner S; Roesler A; Buettner R; Merkelbach-Bruse S
Arch Pathol Lab Med; 2012 Sep; 136(9):983-92. PubMed ID: 22938585
[TBL] [Abstract][Full Text] [Related]
7. High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma.
Ishige T; Itoga S; Sato K; Kitamura K; Nishimura M; Sawai S; Matsushita K; Suzuki K; Ota S; Miyauchi H; Matsubara H; Nakatani Y; Nomura F
Clin Biochem; 2014 Dec; 47(18):340-3. PubMed ID: 25262986
[TBL] [Abstract][Full Text] [Related]
8. Mutation detection in KRAS Exon 1 by constant denaturant capillary electrophoresis in 96 parallel capillaries.
Bjørheim J; Minarik M; Gaudernack G; Ekstrøm PO
Anal Biochem; 2002 May; 304(2):200-5. PubMed ID: 12009696
[TBL] [Abstract][Full Text] [Related]
9. Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
[TBL] [Abstract][Full Text] [Related]
10. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
Fransén K; Klintenäs M; Osterström A; Dimberg J; Monstein HJ; Söderkvist P
Carcinogenesis; 2004 Apr; 25(4):527-33. PubMed ID: 14688025
[TBL] [Abstract][Full Text] [Related]
11. Detection of K-ras exon 1 mutations by constant denaturant capillary electrophoresis.
Zhao C; Xu G; Shi X; Ma J; Lu S; Yang Q
Biomed Chromatogr; 2004 Oct; 18(8):538-41. PubMed ID: 15386519
[TBL] [Abstract][Full Text] [Related]
12. Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms.
Miao J; Kusafuka T; Fukuzawa M
Oncol Rep; 2004 Dec; 12(6):1269-72. PubMed ID: 15547749
[TBL] [Abstract][Full Text] [Related]
13. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
14. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
15. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region.
Amanuel B; Grieu F; Kular J; Millward M; Iacopetta B
Pathology; 2012 Jun; 44(4):357-9. PubMed ID: 22614711
[TBL] [Abstract][Full Text] [Related]
16. Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.
Jarry A; Masson D; Cassagnau E; Parois S; Laboisse C; Denis MG
Mol Cell Probes; 2004 Oct; 18(5):349-52. PubMed ID: 15294323
[TBL] [Abstract][Full Text] [Related]
17. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
18. The T1799A BRAF mutation is present in iris melanoma.
Henriquez F; Janssen C; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4897-900. PubMed ID: 17962436
[TBL] [Abstract][Full Text] [Related]
19. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
[TBL] [Abstract][Full Text] [Related]
20. BRAF mutations in conjunctival melanoma.
Gear H; Williams H; Kemp EG; Roberts F
Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2484-8. PubMed ID: 15277467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
